Vascular Cartographic Scanning Nanodevice (VCSN)
Frank Boehm’s book Nanomedical Device and Systems Design, Challenges, Possibilities, Visions endeavors to explore and present concepts for advanced nanomedical components, devices, and systems that may emerge over the next ~10-30 years. One of these nanodevices is called the Vascular Cartographic Scanning Nanodevice (VCSN) (Figure 1), which would be manifest as an autonomous, ~1 micron in diameter nanomedical device.
Figure 1: Artistic representation of conceptual Vascular Cartographic Scanning Nanodevice (VCSN)
Up to perhaps many thousands, or tens of thousands of VCSN nanodevices might be introduced into the patient intravenously, via ingestion as a pill, through inhalation, transdermally using a patch, or migrate in vivo utilizing a topical gel. Once within the patient their purpose would be to rapidly scan the entire human vasculature down to the smallest capillary lumen (~3 microns in diameter) in ultrahigh-resolution (sub-micron) three-dimensional (3D) digitized format. At all times they would be under the complete control of the surgeon or physician via “outbody” computer commands. Some of the capabilities of the VCSN are listed below:
- Capable of generating a very high-resolution (under 1 micron) 3D rendering of the complete human vasculature down to the smallest capillaries. It may also be applied to the imaging of the lymphatic system, and in a simplified form, the gastrointestinal tract, using a Gastrointestinal Micro Scanning Device (GMSD), (see description below).
- Ability to distinguish vascular and neurological plaque deposits and lesions with high accuracy.
- Capacity to determine vascular wall thicknesses, along with the identification and highlighting of any “hot spot” sites within the vasculature, such as imminent blockages or aneurysms that are at risk of rupturing.
- Surgeon and physicians would be able to “fly-through” all scanned areas via a joystick and computer display for the highly detailed inspection of any desired site within the system. The acquired spatial data from the VCSN may also enable holographic rendering and virtual travel through all imaged systems.
- Ability to facilitate the targeting of tumors by revealing sites of angiogenesis in close proximity to tumor growth sites.
A number of advantages of the VCSN include:
- High compactness and portability as its operation will require a relatively small footprint. This would enable a simple and quick setup and power-up procedures, which will be a boon for applications in developing countries and remote terrestrial environments.In aerospace, it might be utilized as an element of an on board medical diagnostics suite on military and medical aircraft.
- For space travel, it may be reconfigured for integration into spacesuits and spacecraft, and provide a compact yet very powerful medical imaging capability for future Moon and Mars habitats.
- Frugal energy consumption.
- Inexpensive administration and operation
- Rapid scanning time (~5 minutes).
- Ultrahigh resolution digital imagery and inherent flexibility for display across several formats and ease of file transmission to medical personnel globally via secure telecommunications connectivity
- Potential for enabling the significant reduction or elimination of long waiting queues for critical imaging technologies.
Gastrointestinal Micro Scanning Device (GMSD)
The Gastrointestinal Micro Scanning Device (GMSD) (Figure 2) will serve as far less complex precursor to the VCSN as it will not have the capacity for propulsion or navigation. It might, however, employ nascent forms of quantum computing, nanoelectronics, spatial data acquisition, and Pixel Matrix (see below) technologies that are envisaged for the VCSN. Hence, in addition to serving as formative in vivo spatial data acquisition device, the GMSD may also have utility as a test bed of sorts that is employed to identify and resolve technical, integrative, and functional issues toward the development of the VCSN.
Figure 2: Artistic representation of conceptual Gastrointestinal Micro Scanning Device (GMSD)
The GMSD system will consist of three distinct components that work in unison to generate very high-resolution 3D topography of the entire internal surface of the GIT. The GMSD would accomplish this task by utilizing:
- Bright Ball (BB) scanning device, which would have a smooth spherical morphology of ~3 mm in diameter
- Pulse Generator/Data Transfer (PGDT) unit would trigger the activity of the internalized BB device via a specifically encrypted signal. The BB would be activated to scan subsequently to receiving this specific signal only. Once activated, the BB would commence to transmit a constant spatial data stream to the PGDT, which would serve as a data transfer device when linked to a computer and the Pixel Matrix (see below) software. The PGDT would be securely affixed to the patient’s abdominal surface and would stay in place for the duration of the scan.
- The Pixel Matrix display would process the PGDT supplied spatial data toward the reconstruction a high resolution “pixel per hit” 3D rendering of the total scanned area of the GIT that has been traversed by the BB. This software would enable “fly-through” and cross-sectional capabilities, allowing medical personnel to traverse the entire GIT (using a joystick, computer mouse, or touch screen display) to investigate any potential problem areas in great detail. The spatial data might also be converted to holographic and virtual reality formats. Using this procedure, the physician and/or surgeon would thus recognize any anomalous topography that is associated with tumor growth, lesions, and other abnormal features that may exist within the GIT.
The operational procedure for the GMSD would be relatively simple to implement, as the BB would be introduced orally to the patient in the same manner as a pill. Subsequently, an adhesive waterproof thin film PGDT patch would be affixed to the skin of patient’s abdomen. At this juncture, a system calibration would be performed to ensure that the communication link between the BB and the PGDT is functioning properly. An initial test scan would also be conducted in order to configure the image resolution. The PGDT would emit a unique pulsed signal (e.g., ultrasonic, near-infrared), which when received by sensors embedded within the surface of the BB would trigger all of the embedded emitters/receivers to fire and emit their scanning beams simultaneously in every direction. Once these procedures are completed the patient would be allowed to leave the physician’s office, clinic, or hospital to go about his/her normal routine. The internalized BB would now move along with the natural peristaltic rhythms of the GIT and be naturally eliminated at the conclusion of the transit duration. The patient would then return to the facility in two or three days (contingent on the assessed GIT transit time) to have the PGDT patch removed.
During the designated scanning period, the PGDT will have been continuously uploading spatial data provided by the BB, which would then be interfaced with a computer via a USB port to stream all of this data to the PM software housed within the computer. The data would now be translated to high-resolution 3D imagery on a display. The PM software would calculate BB orientation and would correlate the interrogating hits obtained within predetermined parameters to construct a cross section of the GIT to depict its internal topography. These digitized fragments would then be sequentially pieced together to form a seamless spatially accurate rendering of the system.
There is no vaccine or specific treatment for COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2. Since the outbreak began in late 2019, researchers have been racing to [...]
Corona Virus (COVID 19) Interview with Michael Osterholm an expert in infectious disease epidemiology.
Michael Osterholm is an internationally recognized expert in infectious disease epidemiology. He is Regents Professor, McKnight Presidential Endowed Chair in Public Health, the director of the Center for Infectious Disease Research and Policy [...]
With the new coronavirus spreading from person to person (possibly including from people without symptoms), reaching four continents, and traveling faster than SARS, driving it out of existence is looking increasingly unlikely. It’s still [...]
Wake Forest Institute for Regenerative Medicine (WFIRM) scientists have improved upon the 3D bioprinting technique they developed to engineer skeletal muscle as a potential therapy for replacing diseased or damaged muscle tissue, moving another [...]
An international team of scientists from the University of Southampton, the University of Padova, and the University of Zurich has connected a silicon neuron to a neuron from the rat hippocampus with an artificial [...]
In an insightful 42-minute interview, NMIN’s Scientific Director Dr. Pieter Cullis, a pioneer in liposomal gene and drug delivery, discusses his scientific career with a focus on his contributions to the evolution of [...]
A powerful antibiotic that kills some of the most dangerous drug-resistant bacteria in the world has been discovered using artificial intelligence. The drug works in a different way to existing antibacterials and is the [...]
Artificial intelligence hit a big milestone in January — the first drug designed entirely using artificial intelligence entered human clinical trials. The compound, created by Oxford-based biotech company Exscientia, is aimed at treating obsessive-compulsive [...]
Researchers at the Massachusetts General Hospital (MGH) in the US have uncovered the ‘Achilles’ heel’ of most viruses which plague mankind, and could soon develop a universal vaccine. Vaccine research, development and testing takes [...]
Every age in the history of human civilisation has a signature material, from the Stone Age, to the Bronze and Iron Ages. We might even call today’s information-driven society the Silicon Age. Since the [...]
CRISPR gene-edited immune cells have been injected into three people with advanced cancer without any serious side effects, the first trial of its kind in the US. It is also the first CRISPR cancer [...]
“We’ll have nanobots that… connect our neocortex to a synthetic neocortex in the cloud. Our thinking will be a…. biological and non-biological hybrid.” Ray Kurzweil, TED 2014 UPDATE - February 9 2020 Since [...]
Frank Boehm (NanoApps Medical Inc. founder) and Amanda Scott (NA CEO) join NanoApps Athletics Inc. NanoApps Athletics Inc proposes a unique synergistic biochemical/nanomedical strategy for the expedited repair and healing of Achilles tendon micro [...]
In her inaugural podcast, Jamilee interviews Frank Boehm of NanoApps Medical Inc and NanoApps Athletics Inc. From Jamilee's podcast: Welcome to the first episode of "In a Click". On todays show I chat with [...]
Using straightforward chemistry and a mix-and-match, modular strategy, researchers have developed a simple approach that could produce over 65,000 different types of complex nanoparticles, each containing up to six different materials and eight segments, [...]
Researchers have developed an ultra-thin and ultra-flexible electronic material that could be printed and rolled out like newspaper, for the touchscreens of the future. The touch-responsive technology is 100 times thinner than existing touchscreen [...]
Nobody understands what consciousness is or how it works. Nobody understands quantum mechanics either. Could that be more than coincidence? "It is hard to avoid the implication that consciousness and quantum mechanics are [...]
The University of Queensland (UQ) is confident it can develop a vaccine for the potentially deadly coronavirus in as few as 16 weeks are two more people in Brisbane are monitored for the virus. [...]